With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Robert L. Ferris, MD, ...
In this segment focused on advanced renal cell carcinoma, Dr. Geynisman shifts the discussion to patients with intermediate ...
A new cross-sectional analysis reveals that young adult cancer survivors in the United States face a significantly higher ...
Dr. Costa emphasizes that absence of prior BCMA-directed therapy and treatment history represent fundamental elements guiding ...
The FDA has granted a priority review to a new drug application (NDA) for lirafugratinib, a highly selective oral FGFR2 ...
The FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for ...
Determining optimal treatment sequencing after frontline therapy in advanced urothelial carcinoma falls into 2 categories: ...
Matched sibling donors (MSD) and matched unrelated donors (MUD) continue to yield the best 2-year survival outcomes following allogeneic hematopoietic cell transplantation (HCT), while mismatched ...
Benjamin Izar, MD, PhD, discusses unmet needs in melanoma including drug resistance and brain and liver metastases. During a visit to Columbia University’s Herbert Irving Comprehensive Cancer Center, ...
Final analysis from the phase 2 OVATION 2 trial (NCT03393884) has demonstrated a continued and growing overall survival (OS) ...
Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...
Use of the ProSense Cryoablation System in patients with kidney cancer resulted in an 83.9% recurrence-free rate among 112 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results